VERU Veru Inc

Shares of companies in the broader consumer staples space are trading lower amid overall market weakness following weak retail earnings. Worse-than-expected Q1 EPS from Target have weighed on retail and staples stocks on Wednesday.

Shares of companies in the broader consumer staples space are trading lower amid overall market weakness following weak retail earnings. Worse-than-expected Q1 EPS from Target have weighed on retail a

12:34 ET

Brookline Capital Markets Adjusts Price Target for Veru to $31 From $29, Reiterates Buy Rating

11:20 AM EDT, 05/18/2022 (MT Newswires) -- Veru (VERU) has an average hold rating among analysts, with a price target range of $24 to $55. (MT Newswires covers equity, commodity and economic research

05-18 11:23 ET

Unusually active option classes on open May 18th

Unusual total active option classes on open include: Tuscan Holdings Corp (THCA), Genius Brands (GNUS), Walgreen Boots (WBA), TJX (TJX), ChargePoint Holdings (CHPT), Costco (COST), Lowe's (LOW), ZIM I

05-18 09:52 ET

Veru price target raised to $31 from $29 at Brookline

Brookline analyst Kumaraguru Raja raised the firm's price target on Veru to $31 from $29 and keeps a Buy rating on the shares following the Q1 results. The emergency use authorization submission for S

05-18 09:46 ET

Veru Price Target Raised to $31.00/Share From $29.00 by Brookline Capital

Veru Price Target Raised to $31.00/Share From $29.00 by Brookline Capital

05-18 09:39 ET

Veru Is Maintained at Buy by Brookline Capital

Veru Is Maintained at Buy by Brookline Capital

05-18 09:39 ET

Veru analyst ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/18/2022 98.72% Brookline Capital $29 → $31 Maintains Buy 05/13/2022 252.56% Jefferies $33 → $55 Maintai

05-18 09:31 ET

Brookline Capital Maintains Buy on Veru, Raises Price Target to $31

Brookline Capital analyst Kumaraguru Raja maintains Veru (NASDAQ:VERU) with a Buy and raises the price target from $29 to $31.

05-18 09:30 ET

Veru Names Joel Batten Exec VP, Head Of Its US Infectious Disease Franchise

Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers,

05-18 08:34 ET

So What's Up With Veru Shares Rising Today?

Shares of companies in the broader consumer staples sector, including Veru Inc (NASDAQ:VERU), are trading higher as stocks rebound from recent weakness. Stocks have experienced volatility this year am

05-17 03:51 ET